Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Benefit from Beta Interferon in the Treatment of Multiple Sclerosis (CROSBI ID 127437)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Bošnjak-Pašić, Marija ; Lisak, Marijana ; Uremović, Melita ; Vidrih, Branka, Demarin, Vida Benefit from Beta Interferon in the Treatment of Multiple Sclerosis // Acta clinica Croatica, 45 (2006), 1; 37-40-x

Podaci o odgovornosti

Bošnjak-Pašić, Marija ; Lisak, Marijana ; Uremović, Melita ; Vidrih, Branka, Demarin, Vida

engleski

Benefit from Beta Interferon in the Treatment of Multiple Sclerosis

Over the past twelve years, beta interferons la and lb have been inereasingly used as immunomodulatory agents in the treatment of multiple sclerosis as well as for prophylaxis of disease progression. In Croatia, the cost of beta interferons 1a and lb has been covered by the Croatian Institute of Health Insurance since 1997. Despite numerous doubts about their real benefit, having in mind their price, side effects and occurrence of neutralizing antibodies, numerous clinical trials have confirmed their efficacy The most efficient arc interferon beta la (Rebif© in a dose of 12 MIU, subcutaneously, three times per week), interferon beta 16 (Betaferon® in a dose of 8 MIU, subcutaneously, every other day) and interferon beta-la (Avonex® in a dose of 6 MIU weekly intramuscularly).

Multiple sclerosis - drug therapy; Interferons - adverse effects; Treatment outcome; Clinical trials

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

45 (1)

2006.

37-40-x

objavljeno

0353-9466

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost